ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Biotechnology

Fujifilm to supply Novavax with key part of COVID vaccine

Japanese group ties up with US biotech company for late-stage trial

A Novavax COVID-19 candidate vaccine is administered to patients in a Phase 1 clinical trial in this image from Australian Broadcasting Corp. (Photo courtesy of Novavax)

TOKYO -- Fujifilm Holdings will supply an active ingredient for late-stage testing of a coronavirus vaccine being developed by U.S.-based Novavax, the Japanese company said Friday.

Subsidiary Fujifilm Diosynth Biotechnologies is already producing the bulk drug substance for the vaccine candidate at a plant in the U.S. state of North Carolina.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more